Stock 0RAG CERENIS THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Cerenis Therapeutics Stock CINNOBER BOAT

Equities

0RAG

FR0012616852

Biotechnology & Medical Research

Delayed CINNOBER BOAT
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Cerenis Therapeutics -.--% -.--%
03-14 Abionyx Pharma: to benefit from a 1ME grant from Bpifrance CF
03-11 Abionyx: reduced net loss in 2023 CF

Financials

Sales 2023 4.6M 4.99M 6.8M Sales 2024 * 4.6M 4.99M 6.8M Capitalization 40.26M 43.66M 59.49M
Net income 2023 -3M -3.25M -4.43M Net income 2024 * -6M -6.51M -8.87M EV / Sales 2023 9.02 x
Net cash position 2023 * 100K 108K 148K Net cash position 2024 * 3.4M 3.69M 5.02M EV / Sales 2024 * 8.01 x
P/E ratio 2023 *
-8.93 x
P/E ratio 2024 *
-7.81 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 68.01%
More Fundamentals * Assessed data

Chart Cerenis Therapeutics

Dynamic Chart

Latest news about Cerenis Therapeutics

Abionyx Pharma: to benefit from a 1ME grant from Bpifrance CF
Abionyx: reduced net loss in 2023 CF
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Abionyx: CSL Behring fails in heart disease trial CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112 CI
Abionyx: former AbbVie executive appointed CMO CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D CI
Abionyx: Successful completion of third GMP batch of CER-001 CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023. CI
Abionyx: encouraging results in brain fog CF
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023 CI
Abionyx: promising new results in uveitis CF
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I CI
Abionyx: cash position reaches 1.7 million euros CF
Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology 2023 Annual Meeting "Kidney Week" CI
More news

Press releases Cerenis Therapeutics

ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024 BU
ABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023 BU
ABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant BU
ABIONYX Pharma Announces Its 2023 Full-Year Financial Results BU
ABIONYX Pharma announces its financial calendar for the year 2024 BU
More press releases

News in other languages on Cerenis Therapeutics

ABIONYX PHARMA : DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS
Abionyx Pharma: croissance de 18% du chiffre d'affaires au 1er trimestre
ABIONYX Pharma fait le point sur son activité et sa position de trésorerie du 1er trimestre 2024
ABIONYX Pharma : Mise à disposition du document d’enregistrement universel pour l’année 2023
Bollore : Euroapi, Chargeurs, Spie...les valeurs à suivre aujourd'hui à Paris -
More news

Managers and Directors - Cerenis Therapeutics

Managers TitleAgeSince
Cyrille Tupin CEO
 Chief Executive Officer 48 06-12-31
Emmanuel de Fougeroux DFI
 Director of Finance/CFO - 08-04-30
Renee Benghozi CTO
 Chief Tech/Sci/R&D Officer - 15-02-08
Members of the board TitleAgeSince
Olivier Martinez BRD
 Director/Board Member 54 -
Christian Chavy BRD
 Director/Board Member 75 15-02-05
Cyrille Tupin CEO
 Chief Executive Officer 48 06-12-31
More insiders

Company Profile

ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2023, the company boasted a portfolio of 3 products in clinical development.
Sector
Biotechnology & Medical Research
Calendar
2024-08-21 - Q2 2024 Sales and Revenue Release
More about the company

Income Statement Evolution

More financial data

Ratings for Cerenis Therapeutics

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.25 EUR
Average target price
10.5 EUR
Spread / Average Target
+740.00%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+11.91% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.60% 106B
BIONTECH SE Stock BioNTech SE
-4.68% 24.28B
ARGENX SE Stock argenx SE
-0.82% 21.96B
GENMAB A/S Stock Genmab A/S
-10.12% 18.16B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.12% 16.37B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.47% 15.56B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.77% 13.63B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.58% 12.27B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABNX Stock
  4. 0RAG Stock